Develop partnerships that expand the precompetitive space through clinical proof of concept mechanism to accelerate translational learning and to fill critical knowledge gaps in understanding the network biology of drug targets and drug-target interactions.
2030 14.D To Be Initiated Develop partnerships that expand the precompetitive space through clinical proof of concept mechanism to accelerate translational learning... DN 2015 AD Summit: 6E and 6F Public Private Partnerships 2023
Establish at least one precompetitive partnership to validate the therapeutic targets that will be delivered by the Accelerating Medicines Partnership for AD (AMP AD), as well as other pioneer targets, through clinical proof of mechanism/proof of concept.
Summary of Key Accomplishments
This milestone has yet to be initiated. Accomplishments are forthcoming.
The key accomplishments summary is current as of March 2022.